BioMarin Pharmaceuticals, Inc. (BMRN) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $66.53 +0.15%
Revenue Growth %: +32.7%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: +32.7%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported GAAP Q2 EPS of ($0.27), $0.06 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $124 million versus the consensus estimate of $121.54 million.
BioMarin Pharmaceuticals, Inc. sees FY2012 revenue of $475-$510 million, versus the consensus of $494.51 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
BioMarin Pharmaceuticals, Inc. sees FY2012 revenue of $475-$510 million, versus the consensus of $494.51 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
